Miracle Leaf® qualifying-conditions guide

Medical Marijuana for Tourette Syndrome

Neurodevelopmental disorder characterized by multiple motor tics and one or more vocal tics. Cannabis has limited evidence for reducing tic severity in adults with treatment-resistant Tourette syndrome.

Reviewed by Miracle Leaf® Editorial Team

Last reviewed 2026-05-15

Book Evaluation Call (833) LEGAL-MJ

NASEM evidence levelLimitedICD-10: F95.2

What is Tourette Syndrome?

Tourette syndrome (TS) is a neurodevelopmental disorder characterized by multiple motor tics and one or more vocal tics, with onset typically in childhood. Tic severity varies widely; many patients experience meaningful improvement by adulthood, but a significant minority continue to have functionally disabling tics that respond poorly to first-line behavioral and pharmacologic therapies.

Does cannabis help Tourette Syndrome?

The 2017 NASEM consensus report identified limited evidence that THC capsules are effective for treating Tourette syndrome. The evidence base derives primarily from small randomized trials and case series of adult patients with treatment-resistant tics.

Tourette syndrome is a qualifying condition under several state medical cannabis programs, typically restricted to adult patients with documented treatment-refractory disease. Use in pediatric patients requires careful clinical judgment given the developmental effects of THC on the adolescent brain.

Eligibility

State eligibility for Tourette Syndrome

Whether this condition is listed varies by state program. A Miracle Leaf® physician determines eligibility during your evaluation.

State-by-state eligibility for Tourette Syndrome: whether the condition qualifies under Florida, Georgia, and Texas medical cannabis programs.
State	Qualifies?	Program
Florida	Not listed	Florida OMMU
Georgia	Yes	Georgia DPH Low-THC Registry
Texas	Not listed	Texas Compassionate Use Program

Outside Florida, Georgia, or Texas?

Telehealth visits are available in 22 states. See telehealth states

Common questions

Frequently asked questions

How strong is the evidence that cannabis helps Tourette syndrome?

Limited. The 2017 NASEM report identified limited evidence that THC capsules are effective for the treatment of Tourette syndrome. Small clinical studies (primarily in adults with treatment-resistant disease) describe tic reduction with THC-dominant products. Trial sizes are modest and most evidence is from adult populations.

Is any cannabis-derived product FDA-approved for Tourette syndrome?

No. No cannabis or cannabinoid product is FDA-approved for Tourette syndrome. Standard pharmacotherapy uses dopamine antagonists (haloperidol, pimozide, aripiprazole) and alpha-2 agonists (clonidine, guanfacine), alongside behavioral therapies such as Comprehensive Behavioral Intervention for Tics (CBIT).

Is cannabis used in children with Tourette syndrome?

Generally no. Most clinical-trial evidence comes from adults with treatment-resistant tics. Pediatric cannabis use is associated with cognitive and mental-health risk and is not recommended outside of FDA-approved indications (Epidiolex for specific epilepsy syndromes). Tourette syndrome often improves spontaneously by adulthood, which further weighs against pediatric cannabis use.

Which state programs include Tourette syndrome as a qualifying condition?

A growing minority of state medical-cannabis statutes enumerate Tourette syndrome specifically, including Arkansas, Illinois, Iowa, Minnesota, and Ohio. Most state programs cover Tourette patients implicitly under broader categories (severe chronic disease, neurological disorders) rather than naming Tourette in statute.

Sources and citations

NASEM: The Health Effects of Cannabis and Cannabinoids (2017)
“Limited evidence that THC capsules are effective for the treatment of Tourette syndrome.”
Tourette Association of America

Ready to talk with a Miracle Leaf® physician?

Book Evaluation Call (833) LEGAL-MJ Shop Now

Reviewed by Miracle Leaf® Editorial Team. This page summarizes current peer-reviewed evidence and federal guidance and is updated when the source documents materially change.